Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Live Share Price, Invest From India

Contineum Therapeutics, Inc. Class A Common Stock Stock Performance

as on June 4, 2026 at 6:59 am IST

Day's Low
Day's High
$12.20
Day's Price Range
$12.79
$12.51
2.48%
Downside
2.24%
Upside
52 Week's Low
52 Week's High
$3.57
52-Week Price Range
$16.33
$12.51
71.46%
Downside
30.54%
Upside

Contineum Therapeutics, Inc. Class A Common Stock share price movements today

Previous Close: $12.38
Open: $12.43
Volume: 629.2K
Day's Low - High: $12.20 - $12.79
52 Week Low - High: $3.57 - $16.33

Contineum Therapeutics, Inc. Class A Common Stock Historical Returns

1 Month Return: -6.21 %
3 Month Return: -12.2 %
1 Year Return: + 161.18 %
3 Year Return: 0 %
5 Year Return: 0 %

Contineum Therapeutics, Inc. Class A Common Stock Stock Fundamentals & Key Indicators

Check Contineum Therapeutics, Inc. Class A Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$489.4M

EPS (TTM)

-1.6471

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-26.88%

Contineum Therapeutics, Inc. Class A Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Contineum Therapeutics, Inc. Class A Common Stock with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Contineum Therapeutics, Inc. Class A Common Stock	NA	$489.4M	NA	NA	0.00%	NA
Revolution Medicines Inc	BUY	$34.8B	401.69%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc	BUY	$39.5B	94.26%	74.09	12.55%	NA
Vertex Pharmaceuticals Inc	BUY	$111.3B	101.32%	26.05	35.51%	NA
Regeneron Pharmaceuticals Inc	BUY	$63.0B	19.23%	14.66	29.65%	0.58%

Stock Returns calculator for Contineum Therapeutics, Inc. Class A Common Stock Stock including INR - Dollar returns

The Contineum Therapeutics, Inc. Class A Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Contineum Therapeutics, Inc. Class A Common Stock investment value today

Current value as on today

₹2,94,676

Returns

₹1,94,676

(+194.68%)

Returns from Contineum Therapeutics, Inc. Class A Common Stock Stock

₹1,63,924 (+163.92%)

Dollar Impact

₹30,752 (+30.75%)

Indian Investors' Interest in Contineum Therapeutics, Inc. Class A Common Stock Stock

Search interest for Contineum Therapeutics, Inc. Class A Common Stock Stock has increased by 850% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 5, 2026 to June 4, 2026

Change:850% versus previous 30 day period

Contineum Therapeutics, Inc. Class A Common Stock Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	0	-	-	-	-	-
Gross Profit	0	0	0	-	0	-	0	0	0	0
Operating Income	-9	-9	-10	-12	84	-18	-17	-14	-17	-16
EBITDA	-7	-9	-8	-10	-14	-18	-15	-14	-17	-16
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-7	-8	-9	-10	-14	-15	-16	-12	-15	-14
Income Tax Expense	0	-	-	-	-	-	-	-	-	-
Net Income	-7	-8	-9	-10	-14	-15	-16	-12	-15	-14
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-6018.60%	0.00%	0.00%	0.00%	0.00%	0.00%

Contineum Therapeutics, Inc. Class A Common Stock Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	50	-	-
Gross Profit	-	0	50	0	0
Operating Income	-28	-22	-16	-50	-68
EBITDA	-28	-23	23	-42	-67
Interest Expense	0	0	0	-	-
Depreciation	0	0	0	0	0
Income Before Tax	-29	-24	23	-42	-59
Income Tax Expense	0	-	0	-	-
Net Income	-29	-24	22	-42	-59
Net Profit Margin	0.00%	0.00%	45.44%	0.00%	0.00%

Contineum Therapeutics, Inc. Class A Common Stock Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-8	-9	-10	-14	-15	-16	-12	-15	-14
Operating Cash Flow	-8	-8	-6	-10	-14	-15	-12	-13	-16
Investing Cash Flow	8	-38	-30	-9	14	13	14	-47	-39
Financing Cash Flow	0	108	0	0	0	0	19	93	0
Change in Cash	0	60	-36	-18	0	-1	21	32	-55

Contineum Therapeutics, Inc. Class A Common Stock Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-24	22	-42	-59
Operating Cash Flow	-20	19	-32	-55
Investing Cash Flow	22	-65	-69	-3
Financing Cash Flow	-1	56	109	112
Change in Cash	0	9	6	53

Global Institutional Holdings in Contineum Therapeutics, Inc. Class A Common Stock

Funds	Holdings
Great Point Partners LLC	2.14%
BlackRock Inc	1.79%
HHG PLC	7.32%
RA Capital Management, LLC	5.83%
Johnson & Johnson	5.29%

See all

Insights on Contineum Therapeutics, Inc. Class A Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 year, CTNM stock has moved up by 180.7%
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 274.7% return, outperforming this stock by 94.0%

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Organisation	Contineum Therapeutics, Inc. Class A Common Stock
Headquarters	3565 General Atomics Court, San Diego, CA, United States, 92121
Industry	Biotechnology
CEO	Mr. Carmine N. Stengone MBA, MS
E-voting on shares	Click here to vote

Key Management of Contineum Therapeutics, Inc. Class A Common Stock

Name	Title
Mr. Steve E. Kunszabo	Senior Director of Investor Relations & Corporate Communications
Mr. John S. Healy	General Counsel & Corporate Secretary
Ms. Jennifer Patterson	Vice President of Human Resources
Mr. Austin Chen Ph.D.	Senior VP & Head of Research
Mr. Carmine N. Stengone MBA, MS	President, CEO & Director
Mr. Peter T. Slover CPA	Chief Financial Officer
Dr. Timothy R. Watkins M.D., M.Sc.	Chief Medical Officer & Head of Development
Ms. Morgan Paulsen	Senior Manager of Accounting
Dr. Daniel S. Lorrain Ph.D.	Chief Science Officer
Ms. Julie S. Iwashita	Senior Vice President of Clinical Operations

FAQs

What is Contineum Therapeutics, Inc. Class A Common Stock share price today?

Contineum Therapeutics, Inc. Class A Common Stock share price today is $12.51 as on June 4, 2026 at 1:29 am IST at the close of the market. Contineum Therapeutics, Inc. Class A Common Stock share today touched a day high of $12.79 and a low of $12.2.

What is the 52 week high and 52 week low for Contineum Therapeutics, Inc. Class A Common Stock share?

Contineum Therapeutics, Inc. Class A Common Stock share touched a 52 week high of $16.33 on February 24, 2026 and a 52 week low of $3.57 on June 18, 2025. Contineum Therapeutics, Inc. Class A Common Stock stock price today i.e. June 4, 2026 at 1:29 am IST is closed at $12.51,which is 23.39% down from its 52 week high and 250.42% up from its 52 week low.

What is Contineum Therapeutics, Inc. Class A Common Stock's market capitalisation today?

Contineum Therapeutics, Inc. Class A Common Stock market capitalisation is $0.00T as on June 4, 2026 at 1:29 am IST.

How to invest in Contineum Therapeutics, Inc. Class A Common Stock Stock (CTNM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Contineum Therapeutics, Inc. Class A Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Contineum Therapeutics, Inc. Class A Common Stock Shares that will get you 0.1199 shares as per Contineum Therapeutics, Inc. Class A Common Stock share price of $12.51 per share as on June 4, 2026 at 1:29 am IST.

What is the minimum amount required to buy Contineum Therapeutics, Inc. Class A Common Stock Stock (CTNM) from India?

Indian investors can start investing in Contineum Therapeutics, Inc. Class A Common Stock (CTNM) shares with as little as ₹95.695 or $1 (as of June 4, 2026 at 6:47 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in Contineum Therapeutics, Inc. Class A Common Stock stock (as per the Rupee-Dollar exchange rate as on June 4, 2026 at 6:47 am IST). Based on Contineum Therapeutics, Inc. Class A Common Stock share’s latest price of $12.51 as on June 4, 2026 at 1:29 am IST, you will get 0.7994 shares of Contineum Therapeutics, Inc. Class A Common Stock. Learn more about fractional shares .